Search Results for: KDR

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
MAPK1 mitogen-activated protein kinase 1
  • phospho-PLA2 pathway
  • RAF-independent MAPK1/3 activation
  • MAPK1 (ERK2) activation
  • Spry regulation of FGF signaling
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • Frs2-mediated activation
  • ERK/MAPK targets
  • ERK/MAPK targets
  • ERKs are inactivated
  • Regulation of actin dynamics for phagocytic cup formation
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Oncogene Induced Senescence
  • FCERI mediated MAPK activation
  • Regulation of HSF1-mediated heat shock response
  • NCAM signaling for neurite out-growth
  • Recycling pathway of L1
  • RSK activation
  • Signal transduction by L1
  • Activation of the AP-1 family of transcription factors
  • Thrombin signalling through proteinase activated receptors (PARs)
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate NADPH Oxidases
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative feedback regulation of MAPK pathway
  • Negative regulation of MAPK pathway
  • Neutrophil degranulation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signal attenuation
  • Advanced glycosylation endproduct receptor signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • ESR-mediated signaling
  • RUNX2 regulates osteoblast differentiation
  • Regulation of PTEN gene transcription
  • Regulation of the apoptosome activity
  • Estrogen-stimulated signaling through PRKCZ
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Suppression of apoptosis
  • Signaling downstream of RAS mutants
  • Signaling by MAP2K mutants
  • Signaling by MAPK mutants
  • Signaling by RAF1 mutants
  • FCGR3A-mediated phagocytosis
  • Growth hormone receptor signaling
  • Acetylsalicylic acid
  • Minocycline
  • Isoprenaline
  • Arsenic trioxide
  • Olomoucine
  • Phosphonothreonine
  • Purvalanol
  • SB220025
  • Seliciclib
  • Perifosine
  • N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
  • N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
  • (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
  • (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
  • 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
  • (1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
  • 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine
  • Turpentine
  • Ulixertinib
NCK1 NCK adaptor protein 1
  • Downstream signal transduction
  • Generation of second messenger molecules
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • Nephrin family interactions
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • Activation of RAC1
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
NRP1 neuropilin 1
  • Neurophilin interactions with VEGF and VEGFR
  • Signaling by ROBO receptors
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • CRMPs in Sema3A signaling
  • Signal transduction by L1
  • CHL1 interactions
P2RY2 purinergic receptor P2Y2
  • G alpha (q) signalling events
  • P2Y receptors
  • Surfactant metabolism
  • Promethazine
  • Suramin
  • Denufosol
  • INS 316
PDCL3 phosducin like 3
PLCG1 phospholipase C gamma 1
  • ISG15 antiviral mechanism
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PLCG1 events in ERBB2 signaling
  • DAG and IP3 signaling
  • PLC-gamma1 signalling
  • Synthesis of IP3 and IP4 in the cytosol
  • Downstream signal transduction
  • Generation of second messenger molecules
  • Role of phospholipids in phagocytosis
  • Role of phospholipids in phagocytosis
  • PECAM1 interactions
  • EGFR interacts with phospholipase C-gamma
  • DAP12 signaling
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • Role of second messengers in netrin-1 signaling
  • VEGFR2 mediated cell proliferation
  • VEGFR2 mediated cell proliferation
  • Constitutive Signaling by EGFRvIII
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • Activated NTRK2 signals through PLCG1
  • Activated NTRK2 signals through PLCG1
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Activated NTRK3 signals through PLCG1
  • Activated NTRK3 signals through PLCG1
  • FCGR3A-mediated IL10 synthesis
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
PLCG2 phospholipase C gamma 2
  • GPVI-mediated activation cascade
  • Toll Like Receptor 4 (TLR4) Cascade
  • Synthesis of IP3 and IP4 in the cytosol
  • Generation of second messenger molecules
  • Role of phospholipids in phagocytosis
  • DAP12 signaling
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • CLEC7A (Dectin-1) signaling
  • CLEC7A (Dectin-1) signaling
  • Dectin-2 family
  • Dectin-2 family
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • FCGR3A-mediated IL10 synthesis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
PPM1A protein phosphatase, Mg2+/Mn2+ dependent 1A
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Energy dependent regulation of mTOR by LKB1-AMPK
PPM1B protein phosphatase, Mg2+/Mn2+ dependent 1B
  • ISG15 antiviral mechanism
PTPN11 protein tyrosine phosphatase non-receptor type 11
  • Interleukin-6 signaling
  • PI3K Cascade
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • GPVI-mediated activation cascade
  • Prolactin receptor signaling
  • PIP3 activates AKT signaling
  • Spry regulation of FGF signaling
  • Signaling by SCF-KIT
  • GAB1 signalosome
  • Downstream signal transduction
  • PECAM1 interactions
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signaling by Leptin
  • Costimulation by the CD28 family
  • CTLA4 inhibitory signaling
  • PD-1 signaling
  • Signal regulatory protein family interactions
  • Netrin mediated repulsion signals
  • Platelet sensitization by LDL
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Regulation of IFNG signaling
  • RET signaling
  • Interleukin-20 family signaling
  • MET activates PTPN11
  • Regulation of RUNX1 Expression and Activity
  • Interleukin-37 signaling
  • Activated NTRK2 signals through FRS2 and FRS3
  • Interferon alpha/beta signaling
  • Regulation of IFNA signaling
  • Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
  • FLT3 Signaling
  • STAT5 Activation
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Dodecyltrimethylammonium
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Metachondromatosis
PTPN12 protein tyrosine phosphatase non-receptor type 12
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • EGFR downregulation
  • Signaling by PDGF
  • Downregulation of ERBB2 signaling
  • Interleukin-37 signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Tiludronic acid
PTPN6 protein tyrosine phosphatase non-receptor type 6
  • GPVI-mediated activation cascade
  • Regulation of KIT signaling
  • PECAM1 interactions
  • Costimulation by the CD28 family
  • PD-1 signaling
  • Signal regulatory protein family interactions
  • Platelet sensitization by LDL
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • CD22 mediated BCR regulation
  • Neutrophil degranulation
  • Interferon gamma signaling
  • Regulation of IFNG signaling
  • Interleukin-37 signaling
  • Interferon alpha/beta signaling
  • Interleukin receptor SHC signaling
  • Regulation of IFNA signaling
  • Growth hormone receptor signaling
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Tiludronic acid
PTPRR protein tyrosine phosphatase receptor type R
RASA1 RAS p21 protein activator 1
  • Downstream signal transduction
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • VEGFR2 mediated cell proliferation
  • Regulation of RAS by GAPs
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • RASA1-related disorders, including: Parkes-Weber slndrome; Capillary malformation-arteriovenous malformation (CM-AVM); Arteriovenous fistula (AVF)
SERPINF1 serpin family F member 1
  • Copper
SH2D2A SH2 domain containing 2A
  • VEGFA-VEGFR2 Pathway
SHB SH2 domain containing adaptor protein B
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
SHC1 SHC adaptor protein 1
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signalling to RAS
  • Signalling to RAS
  • SHC1 events in EGFR signaling
  • Tie2 Signaling
  • Integrin signaling
  • XBP1(S) activates chaperone genes
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Constitutive Signaling by EGFRvIII
  • RAF/MAP kinase cascade
  • Signal attenuation
  • Insulin receptor signalling cascade
  • Insulin receptor signalling cascade
  • RET signaling
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Interleukin-2 signaling
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Interleukin receptor SHC signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
SHC2 SHC adaptor protein 2
  • Signalling to RAS
  • Signalling to RAS
  • VEGFA-VEGFR2 Pathway
  • RAF/MAP kinase cascade
SRC SRC proto-oncogene, non-receptor tyrosine kinase
  • Signaling by ERBB2
  • Nuclear signaling by ERBB4
  • Downregulation of ERBB4 signaling
  • PIP3 activates AKT signaling
  • GAB1 signalosome
  • Downstream signal transduction
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • G alpha (s) signalling events
  • G alpha (i) signalling events
  • G alpha (i) signalling events
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • Netrin mediated repulsion signals
  • Regulation of commissural axon pathfinding by SLIT and ROBO
  • RAF activation
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PTK2 signaling
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • Regulation of RUNX1 Expression and Activity
  • RUNX2 regulates osteoblast differentiation
  • Regulation of RUNX3 expression and activity
  • Extra-nuclear estrogen signaling
  • Activated NTRK2 signals through FYN
  • Activated NTRK3 signals through PI3K
  • Activated NTRK3 signals through PI3K
  • Long-term potentiation
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric acid
  • Paratoulene phosphate
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • XL228
  • Tirbanibulin
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • PD-168393
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • PP-121
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
  • Nintedanib
  • Fostamatinib

Page 3 out of 4 pages